REG - Integrated Diag Hdgs - EGX Delisting – timeline under EGX's OPR

Integrated Diagnostics HoldingsAnnouncement

13/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240813:nRSM1573Aa&default-theme=true

RNS Number : 1573A  Integrated Diagnostics Holdings PLC  13 August 2024

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO
SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

 

 

Integrated Diagnostics Holdings plc

 

 

EGX Delisting - timeline under EGX's special operations market (OPR)

 

13 August 2024

 

Integrated Diagnostics Holdings plc ("IDH" or the "Company") refers to the
shareholder resolutions passed at the Company's Extraordinary General Meetings
held on 12 June 2024 and 18 July 2024 approving, amongst other things, the
voluntary delisting (the "EGX Delisting") of the Company's ordinary shares
(the "Shares") from the Egyptian Exchange (the "EGX") and the Company's
repurchase of Shares from shareholders who hold Shares traded on the EGX held
by Misr for Central Clearing, Depository and Registry ("EGX Shares", and such
shareholders, "EGX Shareholders") if so required by such EGX Shareholders
during the relevant buyback period (the "Delisting Share Buyback").

 

Pursuant to the Delisting Share Buyback, the Company has today announced the
opening of the EGX's special operations market (OPR) pursuant to which EGX
Shareholders can tender their EGX Shares to the Company during the period from
the commencement of the trading session on Sunday 18 August 2024 to the close
of the trading session on Thursday 22 August 2024, at a price of EGP 20
(twenty Egyptian pounds) per EGX Share. The Company undertakes to purchase all
EGX Shares tendered during this period through the special operations market
(OPR).

 

The brokerage firm representing the Company in the share purchase process
under the special operations market (OPR) is EFG-Hermes International
Securities Brokerage, located at Smart Village, Km 28 - Cairo-Alexandria
Desert Road, Giza.

 

Shareholders should note that, following the close of the special operations
market (OPR) and the subsequent decision of the EGX's Listing Committee to
delist the Company's Shares and remove the same from its database, any EGX
Shares not tendered through the special operations market (OPR) will no longer
be capable of being traded on the EGX and will, subject to all applicable
terms and conditions and all necessary steps having been taken, be capable of
being traded on the main market for listed securities of the London Stock
Exchange, which will become the sole listing venue of the Company.

 

For further information please contact:

 

Integrated Diagnostics Holdings plc

Tarek Yehia

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 |    tarek.yehia@idhcorp.com
(mailto:tarek.yehia@idhcorp.com)

 

Company Secretary

Company Matters

IDHLondon@linkgroup.co.uk (mailto:IDHLondon@linkgroup.co.uk)

 

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

 

IDH is a leading diagnostics services provider in the Middle East and Africa
offering a broad range of clinical pathology and radiology tests to patients
in Egypt, Jordan, Nigeria, Sudan and Saudi Arabia. The Group's core
brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as
Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan (both
in Sudan), and Biolab KSA (Saudi Arabia).  With over 40 years of
experience, a long track record for quality and safety has earned the Company
a trusted reputation, as well as internationally recognised accreditations for
its portfolio of over 3 ,000 diagnostics tests. From its base
of 601 branches as of 31 December 2023, IDH served over 8. 5 million
patients and performed more than 36.1 million tests in 2023.  IDH will
continue to add laboratories through a Hub, Spoke and Spike business model
that provides a scalable platform for efficient expansion.  Beyond organic
growth, the Group targets expansion in appealing markets,
including acquisitions in the Middle Eastern, African, and East Asian
markets where its model is well-suited to capitalise on similar healthcare and
consumer trends and capture a significant share of fragmented markets.  IDH
is a Jersey-registered entity (i) whose shares are admitted to the equity
shares (transition) category (previously, the standard listing segment) of the
Official List of the UK Financial Conduct Authority and admitted to trading on
the main market for listed securities of the London Stock Exchange (ticker:
IDHC) since May 2015, and (ii) with a secondary listing on the Egyptian
Exchange since May 2021 (ticker: IDHC.CA).

 

Learn more at idhcorp.com (http://idhcorp.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPTMRTMTJBBFI